Literature DB >> 27878420

A 5-year clinical follow-up after duty-cycled phased RF ablation of paroxysmal atrial fibrillation.

Antoine Lepillier1, Xavier Copie2, Gilles Lascault2, Olivier Paziaud2, Olivier Piot2.   

Abstract

PURPOSE: Catheter radiofrequency ablation (RFA) is an effective treatment for symptomatic paroxysmal atrial fibrillation (AF). It has been demonstrated that the multielectrode pulmonary vein ablation catheter (PVAC) has favourable outcomes at 6-12 months post-ablation, but there are only few studies with a long-term follow-up.
METHODS: We retrospectively reviewed 77 consecutive PVAC procedures in our centre, from November 2007 to December 2012. RFA was attempted in patients with symptomatic paroxysmal AF (mean age 58.7 ± 9.8 years, 50 men (64.9 %). The ablation strategy consisted of circumferential pulmonary vein isolation (CPVI) with the PVAC system. A questionnaire was used over the follow-up period to assess the efficacy of AF ablation. Success was defined as freedom from AF/atrial flutter or atrial arrhythmia for a period ranging from 3 to 12 months or more.
RESULTS: Seventy-seven patients were included with paroxysmal AF. The mean duration of the procedure was 99.6 ± 26 min and fluoroscopy time 19.4 ± 6.8 min. Time of RFA was 22.4 ± 5.8 min. Acute complication rate was 10.4 % (the most frequent was vascular injury for 6 patients 7.8 %, 1 patient presented sepsis (1.3 %), 1 patient presented transient ischemic stroke). After a single procedure at a mean FU of 55 ± 11 months, 54/77 (70.1 %) patients were free of symptomatic AF.
CONCLUSIONS: These long-term results suggest that PVAC is an efficient system for CPVI of symptomatic paroxysmal AF.

Entities:  

Keywords:  Atrial fibrillation ablation

Mesh:

Year:  2016        PMID: 27878420     DOI: 10.1007/s10840-016-0199-1

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  22 in total

1.  Conventional radiofrequency catheter ablation compared to multi-electrode ablation for atrial fibrillation.

Authors:  Pim Gal; Alissa E S M Aarntzen; Jaap Jan J Smit; Ahmet Adiyaman; Anand R Ramdat Misier; Peter Paul H M Delnoy; Arif Elvan
Journal:  Int J Cardiol       Date:  2014-08-13       Impact factor: 4.164

2.  One-year clinical outcome after ablation with a novel multipolar irrigated ablation catheter for treatment of atrial fibrillation: potential implications for clinical use.

Authors:  Reza Wakili; Johannes Siebermair; Stephanie Fichtner; Moritz F Sinner; Eva Klocker; Lucia Olesch; Jan N Hilberath; Samira Sarai; Sebastian Clauss; Stefan Sattler; Stefan Kääb; Heidi L Estner
Journal:  Europace       Date:  2016-01-11       Impact factor: 5.214

3.  Predictability of lesion durability for AF ablation using phased radiofrequency: Power, temperature, and duration impact creation of transmural lesions.

Authors:  Mélèze Hocini; Cathy Condie; Mark T Stewart; Nicole Kirchhof; Jason D Foell
Journal:  Heart Rhythm       Date:  2016-02-24       Impact factor: 6.343

4.  Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Authors:  Riccardo Cappato; Hugh Calkins; Shih-Ann Chen; Wyn Davies; Yoshito Iesaka; Jonathan Kalman; You-Ho Kim; George Klein; Douglas Packer; Allan Skanes
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

5.  Evaluation of pulmonary vein stenosis after pulmonary vein isolation using a novel circular mapping and ablation catheter (PVAC).

Authors:  Christian von Bary; Stefan Weber; Christian Dornia; Christoph Eissnert; Claudia Fellner; Philipp Latzin; Sabine Fredersdorf; Stefan Stadler; Okka W Hamer
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-08-13

6.  Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation.

Authors:  Fiorenzo Gaita; Domenico Caponi; Martina Pianelli; Marco Scaglione; Elisabetta Toso; Federico Cesarani; Carlo Boffano; Giovanni Gandini; Maria Consuelo Valentini; Roberto De Ponti; Franck Halimi; Jean François Leclercq
Journal:  Circulation       Date:  2010-10-11       Impact factor: 29.690

7.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.

Authors:  M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

8.  nMARQ Ablation for Atrial Fibrillation: Results from a Multicenter Study.

Authors:  Saagar Mahida; Darren A Hooks; Karin Nentwich; G Andre Ng; Massimo Grimaldi; Dong-In Shin; Nicolas Derval; Frederic Sacher; Benjamin Berte; Seigo Yamashita; Arnaud Denis; Mélèze Hocini; Thomas Deneke; Michel Haissaguerre; Pierre Jais
Journal:  J Cardiovasc Electrophysiol       Date:  2015-06-16

9.  Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation.

Authors:  Hakan Oral; Christoph Scharf; Aman Chugh; Burr Hall; Peter Cheung; Eric Good; Srikar Veerareddy; Frank Pelosi; Fred Morady
Journal:  Circulation       Date:  2003-10-13       Impact factor: 29.690

10.  Phased RF ablation in persistent atrial fibrillation.

Authors:  John Hummel; Gregory Michaud; Robert Hoyt; David DeLurgio; Abdi Rasekh; Fred Kusumoto; Michael Giudici; Dan Dan; David Tschopp; Hugh Calkins; Lucas Boersma
Journal:  Heart Rhythm       Date:  2013-11-14       Impact factor: 6.343

View more
  2 in total

1.  Ablation of atrial fibrillation: single-shot techniques poised to dominate rhythm control strategies/the future is here.

Authors:  Antonis S Manolis
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Clinical outcomes of AF patients treated with the first and second-generation of circular mapping and ablation catheter: insights from a real world multicenter experience.

Authors:  Giovanni Rovaris; Paolo De Filippo; Francesco Laurenzi; Gabriele Zanotto; Nicola Bottoni; Mattia Pozzi; Fabrizio Giofrè; Piergiuseppe De Girolamo; Emanuela Visentin; Elena Piazzi; Paola Ferrari
Journal:  J Interv Card Electrophysiol       Date:  2017-09-05       Impact factor: 1.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.